Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.77 |
| ▸ | THRB | P10828 | 7/20 | 0.77 |
| ▸ | BLM | P54132 | 7/20 | 0.77 |
| ▸ | RECQL | P46063 | 6/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | TOP2A | P11388 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.77 |
| ▸ | STAT6 | P42226 | 4/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18071933 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL20427942 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL1103794 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751652 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14341789 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL12368761 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751207 | 1.00 | MEN1 (0.77) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL18751205 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14703485 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL14706187 | 0.95 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369614-B2 | Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220062417-A1 | THERAPY | INNOVATION ULSTER LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20190328742-A1 | TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2019-10-31 | — | — | US | disclosed |
| US-20180185321-A1 | TALC-BOUND COMPOSITIONS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-07-05 | — | — | US | disclosed |
| US-9994444-B2 | Bridged polycyclic compound based compositions for the inhibition and amelioration of disease | ALLACCEM, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2018047197-A1 | SITE-SELECTIVE PEPTIDES AND PROTEIN LABELLING AND SYNTHESIS OF HOMOGENOUS PROTEIN CONJUGATES | Indian Institute Of Science Education And Research Bhopal (IN) | 2018-03-15 | — | — | WO | disclosed |
| US-20170252453-A9 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | ANYGEN CO., LTD. (KR) | 2017-09-07 | — | — | US | disclosed |
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185321-A1 | TALC-BOUND COMPOSITIONS AND USES THEREOF | SSB, UACA, TTR | MEN1 667/4885KMT2A 3904/4885THRB 3667/4885 |
| US-11369614-B2 | Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same | TTPA, FOLR2, FOLR1 | MEN1 4031/4885KMT2A 4205/4885THRB 555/4885 |
| US-20170252453-A9 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | SI, PIGS, MUC1 | MEN1 2885/4885KMT2A 3930/4885THRB 2130/4885 |
| US-20220062417-A1 | THERAPY | CD274, PDCD1, PDCD1LG2 | MEN1 423/4885KMT2A 3991/4885THRB 4651/4885 |
| US-20190328742-A1 | TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | TTPA, FOLR2, FOLR1 | MEN1 4031/4885KMT2A 4205/4885THRB 555/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | MEN1 552/4885KMT2A 2822/4885THRB 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.